

Education:

M.D. cum laude University of Pavia (start 10/2004 - end 7/2010)
Postgraduate degree cum laude in Internal Medicine, University of Pavia (start July 2011 – end June 2016)
Research Fellow, Hematology, Mayo Clinic, Rochester, MN, USA, with Prof. Angela Dispenzieri (4/2015 to 5/2016).
Research Collaborator, Hematology, Mayo Clinic, with Prof. Angela Dispenzieri (start 5/2016 - end 5/2018)
PhD program in Experimental Medicine, University of Pavia (start 10/2015- end 10/2018)
Abilitazione Scientifica Nazionale (ASN) Sett. concorsuale Biochimica Clinica e Biologia Mol. Clinica (05/E3) (11/2020)

Internship and Fellowship: Internal Medicine, Amyloidosis Research and Treatment Center, University of Pavia, with Prof Giampaolo Merlini (2008-2016).

Professional Experience: Consultant, Amyloidosis Research and Treatment Center, Biotechnology Research Laboratories, University Hospital “San Matteo”, Pavia, February 2017 – ongoing.

Assistant Professor in Clinical Chemistry (ricercatore a tempo determinato di tipo B, SSD BIO/12) – from October 2022.

Societies:

2010: Italian Society of Amyloidosis;
2010: International Amyloidosis Society (ISA), Member at Large [March 2020-September 2022]
2011: Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SiBioC);
2012: Italian Society of Internal Medicine (SIMI);
2014: European Hematology Association (EHA) Member of the Sponsor and Fundraising Committee (July 2021- ongoing);
2016: American Society of Hematology (ASH); International Myeloma Society (IMS);
2019: Italian Society of Hematology (SIE).

Awards:

Research Award “Prof. Alberto Malliani” – Italian Society of Internal Medicine (SIMI) (2020).
Fellowship Award “Giancarlo Parisi – Società Italiana di Ematologia” – SIE (2020-2022)
Ghislieri College – “Progetti in Biologia e Medicina” Fellowship Award (2019).
Fondazione “Carlo Chianello”, University of Palermo (Italy) – Fellowship Award (2018).
Clinical Research Training in Hematology (CRTH) of the European Hematology Association (2017-2018).
Italian Society of Clinical Biochemistry (SiBioC) – Award for the best publication of Young Researcher, October 2017.
European Hematology Association (EHA) – Travel Grant EHA meeting, Madrid (Spain), 2017 and Wien (Austria), 2015.
International Myeloma Society (IMS) – Travel Grant IMW New Delhi (India), March 2017.
American Society of Hematology (ASH) – Abstract Achievement Award, ASH meeting Orlando (FL), December 2015.
Italian Society of Clinical Biochemistry and Clinical Molecular Biology – Best poster presentation, October 2014.
Amyloidosis Foundation “Junior Researcher Travel Award” – ISA Symposiums 2012, 2014 and 2016.
International Society of Amyloidosis – Best Presentation for Young Researcher – ISA Symposium 2012 and 2016.
Italian Society of Internal Medicine (SIMI) – Aventis Foundation award (2012).
Ghislieri College – “Progetti in Biologia e Medicina” Fellowship Award (2012).

Reviewer for the following peer-reviewed journals:

Amyloid, Hematology Reports, Journal of Nephrology, Oncology Reviews, Expert Opinion On Pharmacotherapy, American Journal of Kidney Disease, Biology of Blood and Bone Marrow Transplant, Breathe (European Respiratory Society Educational Program), Polish Archives of Internal Medicine, Orphanet Journal of Rare Diseases, Advances in Medical Sciences, ESC Heart Failure, Postgraduate Medicine, Clinical Chemistry and Laboratory Medicine, Haematologica, Biotechnology and Applied Biochemistry, European Journal of Hematology, Blood Cancer Journal, American Journal of Respiratory and Critical Care Medicine, European Journal of Pharmacology, PLOS ONE.

Ongoing Research Support:

1. Project TRS-2018-00001624: *A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis.* Role: Principal Investigator; Founding agency: Italian Medicine Agency (AIFA)
2. Project GR-2018-12368387: *Towards effective, patient-tailored anti-plasma cell therapies in AL amyloidosis: Predicting drug response and overcoming drug resistance.* Role: Co-Principal Investigator; Founding Agency: Ministry of Health (MoH)
3. Grant n. 61370121: *The Italian transthyretin amyloidosis web network.* Role: Principal Investigator; Founding agency: Global Bridges – Mayo Clinic and Pfizer.

- Schulte T, Chaves-Sanjuan A, Mazzini G, Speranzini V, Lavatelli F, Ferri F, Palizzotto C, Mazza M, [Milani P](#), Nuvolone M, Vogt AC, Vogel M, Palladini G, Merlini G, Bolognesi M, Ferro S, Zini E, Ricagno S. Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter. *Nat Commun.* 2022 Nov 17;13(1):7041.
- Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, [Milani P](#), Merlini G, Schönland S, Veelken K, Hegenbart U, Geyer SM, Kumar SK, Kastiris E, Dimopoulos MA, Liedtke M, Witteles R, Sanchorawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. *J Clin Oncol.* 2022 Oct 10 [Online ahead of print].
- Havasi A, Heybeli C, Leung N, Angel-Korman A, Sanchorawala V, Cohen O, Wechalekar A, Bridoux F, Jaffer I, Gutgarts V, Hassoun H, Levinson M, Rosenbaum C, [Milani P](#), Palladini G, Merlini G, Hegenbart U, Schönland S, Veelken K, Pogrebinsky A, Doros G, Landau H. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group. *Blood Cancer J.* 2022 Aug 18;12(8):119.
- Cascino P, Nevone A, Piscitelli M, Scopelliti C, Girelli M, Mazzini G, Caminito S, Russo G, [Milani P](#), Basset M, Foli A, Fazio F, Casarini S, Massa M, Bozzola M, Ripepi J, Sesta MA, Acquafredda G, De Cicco M, Moretta A, Rognoni P, Milan E, Ricagno S, Lavatelli F, Petrucci MT, Miho E, Klersy C, Merlini G, Palladini G, Nuvolone M. Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies. *Am J Hematol.* 2022 Aug 9 [Epub ahead of print]
- Palladini G, [Milani P](#). Advances in the treatment of light chain amyloidosis. *Curr Opin Oncol.* 2022 Aug 5 [Epub ahead of print]
- Nevone A, Girelli M, Mangiacavalli S, Paiva B, [Milani P](#), Cascino P, Piscitelli M, Speranzini V, Cartia CS, Benvenuti P, Goicoechea I, Fazio F, Basset M, Foli A, Nanci M, Mazzini G, Caminito S, Sesta MA, Casarini S, Rognoni P, Lavatelli F, Petrucci MT, Olimpieri PP, Ricagno S, Arcaini L, Merlini G, Palladini G, Nuvolone M. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis. *Leukemia.* 2022 Aug;36(8):2076-2085.
- Basset M, [Milani P](#), Foli A, Nuvolone M, Benvenuti P, Nanci M, Fabris F, Bellofiore C, Merlini G, Palladini G. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. *Blood.* 2022 Jun 30 [Epub ahead of print]
- Palladini G, [Milani P](#), Merlini G. In search of the most effective therapy for light chain amyloidosis. *Amyloid.* 2022 Mar;29(1):67-68.
- Basset M, [Milani P](#), Ferretti VV, Nuvolone M, Foli A, Benigna F, Nanci M, Bozzola M, Ripepi J, Sesta M, Russo F, Bosoni T, Klersy C, Albertini R, Merlini G, Palladini G. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. *Clin Chem Lab Med.* 2022 Feb 23;60(3):386-393.
- Riva A, Sturla F, Pica S, Camporeale A, Tondi L, Saitta S, Caimi A, Giese D, Palladini G, [Milani P](#), Castelvechio S, Menicanti L, Redaelli A, Lombardi M, Votta E. Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies. *J Magn Reson Imaging.* 2022 Jan 24 [Epub ahead of print]
- Mazzini G, Ricagno S, Caminito S, Rognoni P, [Milani P](#), Nuvolone M, Basset M, Foli A, Russo R, Merlini G, Palladini G, Lavatelli F. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. *FEBS J.* 2021 Sep 5. [Online ahead of print].
- Palladini G, Celant S, [Milani P](#), Summa V, Affronti G, Olimpieri PP, Petraglia S, Foli A, Nuvolone M, Merlini G, Russo P. A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis. *Leuk Lymphoma.* 2021 Aug 27:1-7.
- Saunders CN, Chattopadhyay S, Huhn S, Weinhold N, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Landi S, Goldschmidt H, [Milani P](#), Merlini G, Rowcien D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Försti A, Houlston R, Hemminki K. Search for AL amyloidosis risk factors using Mendelian randomization. *Blood Adv.* 2021 Jul 13;5(13):2725-2731.
- Aimo A, Rapezzi C, Perfetto F, Cappelli F, Palladini G, Obici L, Merlini G, Di Bella G, Serenelli M, Zampieri M, [Milani P](#), Licordari R, Teresi L, Ribarich N, Castiglione V, Quattrone F, De Rosis S, Vergaro G, Panichella G, Emdin M, Passino C. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. *Eur J Clin Invest.* 2021 May 12:e13598.
- Palladini G, [Milani P](#). The quest for validated treatment endpoints in light chain (AL) amyloidosis: composite criteria for a composite disease. *Leuk Lymphoma.* 2021 Apr 21:1-2.
- Palladini G, [Milani P](#), Malavasi F, Merlini G. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. *Cells.* 2021 Mar 4;10(3):545.
- Palladini G, Paiva B, Wechalekar A, Massa M, [Milani P](#), Lasa M, Ravichandran S, Krsnik I, Basset M, Burgos L, Nuvolone M, Lecumberri R, Foli A, Puig N, Sesta MA, Bozzola M, Cascino P, Nevone A, Ripepi J, Berti P, Casarini S, Annibali O, Orfao A, San-Miguel J, Merlini G. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. *Blood Cancer J.* 2021 Feb 16;11(2):34.

18. Riva A, Sturla F, Caimi A, Pica S, Giese D, Milani P, Palladini G, Lombardi M, Redaelli A, Votta E. 4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis. *J Biomech*. 2021 Feb 8; 119:110308.
19. Palladini G, Schönland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, Milani P, Ando Y, Westermark P, Dispenzieri A, Merlini G. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. *Amyloid*. 2021 Jan 7.
20. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. *Hematology Am Soc Hematol Educ Program*. 2020 Dec 4;2020(1):363-371.
21. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. *Blood*. 2020 Dec 3;136(23):2620-2627.
22. Tirelli C, Zanframundo G, Valentini A, Bortolotto C, Dore R, Oggionni T, Milani P, Bravi E, Kadija Z, Mariani F, Codullo V, Morbini P, Palladini G, Meloni F, Cavagna L. CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL- k amyloidosis. *Radiol Case Rep*. 2020 Sep 14;15(11):2331-2334.
23. Lavatelli F, Mazzini G, Ricagno S, Iavarone F, Rognoni P, Milani P, Nuvolone M, Swuec P, Caminito S, Tasaki M, Chaves-Sanjuan A, Urbani A, Merlini G, Palladini G. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. *J Biol Chem*. 2020 Dec 4;295(49):16572-16584.
24. Basset M, Milani P, Nuvolone M, Benigna F, Rodigari L, Foli A, Merlini G, Palladini G. Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. *Blood Adv*. 2020 Sep 8;4(17):4175-4179.
25. Milani P, Basset M, Nuvolone M, Benigna F, Rodigari L, Lavatelli F, Foli A, Merlini G, Palladini G. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. *Blood Cancer J*, 2020 Sep 1;10(8):90.
26. Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, Mollee P, Hájek R, Moreau P, Jaccard A, Schönland SO, Filshie R, Nicolas-Virelizier E, Augustson B, Mateos MV, Wechalekar A, Hachulla E, Milani P, Dimopoulos MA, Femand JP, Foli A, Gavriatopoulou M, Klersy C, Palumbo A, Sonneveld P, Johnsen HE, Merlini G, Palladini G. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. *J Clin Oncol*, 2020 Oct 1;38(28):3252-3260.
27. Milani P, Sharpley F, Schönland SO, Basset M, Mahmood S, Nuvolone M, Kimmich C, Foli A, Sachchithanatham S, Merlini G, Wechalekar A, Palladini G, Hegenbart U. Pomalidomide and Dexamethasone Grant Rapid Haematologic Responses in Patients With Relapsed and Refractory AL Amyloidosis: A European Retrospective Series of 153 Patients. *Amyloid*. 2020 May 25;1-6.
28. Milani P, Palladini G. Conventional Therapy for Amyloid Light-Chain Amyloidosis. *Acta Haematol*. 2020 Apr 30;1-8.
29. Milani P, Basset M, Curci P, Foli A, Rizzi R, Nuvolone M, Guido R, Gesualdo L, Specchia G, Merlini G, Palladini G. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. *Blood Adv*. 2020 Apr 14;4(7):1321-1324.
30. Sidana S, Milani P, Binder M, Basset M, Tandon N, Foli A, Dispenzieri A, Gertz MA, Hayman SR, Buadi FK, Lacy MQ, Kapoor P, Leung N, Rajkumar SV, Merlini G, Palladini G, Kumar SK. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. *Blood Cancer J*. 2020 Apr 14;10(4):41.
31. Milani P, Fazio F, Basset M, Berno T, Larocca A, Foli A, Riva M, Benigna F, Oliva S, Nuvolone M, Rodigari L, Petrucci MT, Merlini G, Palladini G. High rate of profound clonal and renal responses with Daratumumab treatment in heavily pre-treated patients with AL amyloidosis and high bone marrow plasma cell infiltrate. *Am J Hematol*. 2020 Aug;95(8):900-905.
32. Caccialanza R, Cereda E, Klersy C, Milani P, Cappello S, Martinelli V, Turri A, Basset M, Borioli V, Nuvolone M, Caraccia M, Lavatelli F, Masi S, Lobascio F, Foli A, Merlini G, Palladini G. Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. *Amyloid*. 2020 Mar 26;1-6.
33. Palladini G, Milani P, Merlini G. A powerful oral triplet for AL amyloidosis. *Br J Haematol*. 2020 2020 May;189(4):605-606.
34. Basset M, Defrancesco I, Milani P, Nuvolone M, Rattotti S, Foli A, Mangiacavalli S, Varettoni M, Benvenuti P, Cartia CS, Paulli M, Merlini G, Arcaini L, Palladini G. Non-lymphoplasmacytic lymphomas underlying light chain amyloidosis: distinct clinical features and outcome. *Blood* 2020 Jan 23;135(4):293-296.
35. Chattopadhyay S, Thomsen H, Weinhold N, Meziane I, Huhn S, da Silva Filho MI, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Landi S, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Houlston R, Goldschmidt H, Hemminki K, Försti A. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. *Leukemia* 2020 Apr;34(4):1187-1191.
36. Milani P, Mussinelli R, Perlini S, Palladini G, Obici L. An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis. *Expert Opin Pharmacother*. 2019 Dec;20(18):2223-2228.
37. Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F. Simple, reliable detection of amyloid in Blood. 2019 Jul 18;134(3):320-323.

38. Palladini G, Milani P, Merlini G. Predicting survival in light chain amyloidosis. *Haematologica*. 2019 Jul;104(7):1294-1296.
39. Albanese A, Cocco A, Milani P, Lalli S, Palladini G. Parkinsonism and dysautonomia: Multiple system atrophy. *Parkinsonism Relat Disord*. 2019 2019 May 3;S1353-8020(19)30226-3.
40. Swuec P, Lavatelli F, Tasaki M, Paisonni C, Rognoni P, Maritan M, Brambilla F, Milani P, Mauri P, Camilloni C, et al. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. *Nat Commun*. 2019 Mar 20;10(1):1269.
41. Ami D, Mereghetti P, Foli A, Tasaki M, Milani P, Nuvolone M, Palladini G, Merlini G, Lavatelli F, Nataello A. ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis. *Anal Chem*. 2019 Feb 19;91(4):2894-2900.
42. Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. *Blood* Nov 1;132(18):1988-1991.
43. Kourelis T, Murray DL, Dasari S, Kumar S, Barnidge D, Madden B, Arendt B, Milani P, Merlini G, Ramirez-Alvarado M, Kyle RA, Dispenzieri A. MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. *Am J Hematol* 2018 Nov;93(11):E368-E370.
44. Kumar S, Murray D, Dasari S, Milani P, Barnidge D, Madden B, Kourelis T, Arendt B, Merlini G, Ramirez-Alvarado M, Dispenzieri A. Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. *Leukemia* 2019 Jan;33(1):254-257.
45. Nuvolone M, Milani P, Palladini G, Merlini G. Management of the elderly patient with AL amyloidosis. *Eur J Intern Med* 2018 Dec;58:48-56.
46. Milani P, Merlini G, Palladini G. Novel Therapies in Light Chain Amyloidosis. *Kidney Int Rep* 2017 Nov 28;3(3):530-541
47. Milani P, Dispenzieri A, Scott C, Gertz M, Perlini S, Mussinelli R, Lacy M, Buadi F, Kumar S, Maurer M, Merlini G, Hayman S, Leung N, Dingli D, Klarich K, Lust J, Lin Y, Kapoor P, Go R, Pellikka P, Hwa Y, Zeldenrust S, Kyle R, Rajkumar V, Grogan M. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circulation: Cardiovascular Imaging*. 2018 May;11(5):e006588.
48. Milani P, Merlini G, Palladini G. Light Chain Amyloidosis. *Mediterranean journal of hematology and infectious diseases*. 2018; 10(1):e2018022.
49. Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis Papaiakevou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G. Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis. *Blood*. 2018 Apr 5;131(14):1568-1575.
50. Milani P, Palladini G, Merlini G. New concepts in the treatment and diagnosis of amyloidosis. *Expert review of hematology*. 2018; 11(2):117-127.
51. Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G. Presentation and outcome with second line treatment in AL amyloidosis previously sensitive to non-transplant therapies. *Blood*. 2018 Feb 1;131(5):525-532
52. Imperlini E, Gneccchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Palladini G, Orrù S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, Lavatelli F. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. *Scientific reports*. 2017; 7(1):15661.
53. Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. *Eur Respir Rev*. 2017 Sep 6;26(145).
54. Milani P, Gertz MA, Merlini G, Dispenzieri A. Attitudes about when and how to treat patients with AL amyloidosis: an international survey. *Amyloid*. 2017 Aug 31:1-4.
55. Mezziane I, Huhn S, da Silva Filho MI, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowczenio D, Hawkins P, Hegenbarth U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K. Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. *Haematologica*, 2017 102(10):e411-e414.
56. Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light chain (AL) amyloidosis and low free light chain burden have distinct clinical features and outcome. *Blood*. 2017, 130(5):625-631.
57. Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, Dasari S, Dispenzieri A. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. *Am J Hematol*. 2017 Aug;92(8):772-779.
58. Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, Nuvolone M, Casarini S, Obici L, Merlini G. Prognostication of survival and progression to dialysis in AA amyloidosis. *Amyloid*. 2017 Mar;24(sup1):136-137.
59. Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Perlini S, Merlini G. Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. *Amyloid*. 2017 Mar;24(sup1):54-55.

60. Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U. Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. *Amyloid*. 2017 Mar;24(sup1):56-57.
61. Russo F, Valentini V, Basset M, Bosoni T, Milani P, Ferraro G, Pirolini L, Foli A, Lavatelli F, Belvisi F, Consogno G, Nuvolone M, Li Bergolis F, Bozzola M, Albertini R, Palladini G, Merlini G. Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. *Amyloid*. 2017 Mar;24(sup1):66-67.
62. Palladini G, Milani P, Basset M, Russo F, Lavatelli F, Nuvolone M, Ferraro G, Bozzola M, Foli A, Merlini G. Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. *Amyloid*. 2017 Mar;24(sup1):68-69.
63. Basset M, Milani P, Russo F, Lavatelli F, Nuvolone M, Foli A, Perlini S, Palladini G, Merlini G. Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. *Amyloid*. 2017 Mar;24(sup1):60-61.
64. Milani P, Basset M, Russo F, Foli A, Lavatelli F, Nuvolone M, Ferraro G, Palladini G, Merlini G. Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. *Amyloid*. 2017 Mar;24(sup1):64-65.
65. Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. *Clin Chem Lab Med*. 2017 Oct 26;55(11):1734-1743.
66. Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, Palladini G, Milani P, Cerruti F, Cascio P, Casarini S, Rognoni P, Touvier T, Marcatti M, Ciceri F, Mangiacavalli S, Corso A, Merlini G, Cenci S. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. *Blood*. 2017 Apr 13;129(15):2132-2142.
67. Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G. A phase II trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. *Blood*. 2017 Apr 13;129(15):2120-2123.
68. da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Morgan GJ, Houlston R, Goldschmidt H, Jauch A, Milani P, Merlini G, Rowczenio D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Hemminki K. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. *Leukemia*. 2017 Aug;31(8):1735-1742.
69. Gonsalves WI, Milani P, Derudas D, Buadi FK. The next generation of novel therapies for the management of relapsed multiple myeloma. *Future Oncol*. 2017 Jan;13(1):63-75.
70. Milani P, Rajkumar VS, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *Am J Hematol*. 2016 Nov;91(11):1129-1134.
71. Milani P, Merlini G. Monoclonal IgM-related AL amyloidosis. *Best practice & research. Clinical haematology*. 2016; 29(2):241-248.
72. Milani P, Palladini G, Merlini G. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. *Scand J Clin Lab Invest Suppl*. 2016;245:S113-8.
73. Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A, Wechalekar A, Berk J, Quarta C, Grogan M, Lachmann H, Bokhari S, Castano A, Dorbala S, Johnson G, Glaudemans A, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti P, Flatman K, Vonberg F, Whelan C, Ruberg F, Miller E, Hutt D, Hazenberg B, Rapezzi C, Hawkins P. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation* 2016. 14;133(24):2404-12.
74. Palladini G, Milani P, Foli A, Basset M, Russo F, Bosoni T, Pirolini L, Valentini V, Ferraro G, Lavatelli F, Barassi A, Albertini R, Merlini G. The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. *Clin Chem Lab Med* 2016. 1;54(6):939-45.
75. Milani P, Valentini V, Ferraro G, Basset M, Russo F, Foli A, Palladini G, Merlini G. A patient with AL amyloidosis with negative free light chain results. *Clin Chem Lab Med*. 2016. 1;54(6):1035-7.
76. Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis. *Expert Rev Cardiovasc Ther*. 2015 Nov; 13(11):1195-211.
77. Caccialanza R, Palladini G, Cereda E, Bonardi C, Milani P, Cameletti B, Quarleri L, Cappello S, Foli A, Lavatelli F, Klersy C, Merlini G. Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. *Nutrition*. 2015;31(10):1228-34.
78. Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann E, Basset M, Hawkins P, Merlini G, Wechalekar AD. A European collaborative study of cyclophosphamide, bortezomib and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood*. 2015;126(5):612-5.
79. Fernández de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, Obici L, Milani P, Capello GL, Paulli M, Palladini G, Merlini G. A practical approach to the diagnosis of systemic amyloidoses *Blood* 2015; 125(14):2239-4.
80. Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, Nuvolone M, Obici L, Perlini S, Merlini G. Melphalan and dexamethasone with or without bortezomib in newly-diagnosed AL amyloidosis: a matched case control study on 174 patients. *Leukemia* 2014; 28(12):2311-6.

81. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, Albertini R, Moratti R, Merlini G, Schoenland SO. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. *Blood* 2014; 124: 2325-2332.
82. Perlini S, Salinaro F, Musca F, Mussinelli R, Boldrini M, Raimondi A, Milani P, Foli A, Cappelli F, Perfetto F, Palladini G, Rapezzi C, Merlini G. Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. *J Hypertens* 2014; 32: 1121-1131.
83. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, Caccialanza R, Perlini S, Merlini G. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. *Haematologica* 2014; 99: 743-750.
84. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Quarleri L, Montagna E, Foli A, Milani P, Lavatelli F, Marena C, Merlini G. Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. *JPEN J Parenter Enteral Nutr* 2014; 38: 891-894.
85. Wechalekar AD, Schoenland S, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 Patients with Stage III AL amyloidosis. *Blood* 2013; 121(17):3420-7.
86. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, Perlini S, Merlini G. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. *Haematologica* 2013; 98: 433-436.
87. Palladini G, Foli A, Milani P, Russo P, Albertini L, Lavatelli F, Obici L, Perlini S, Moratti R, Merlini G. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. *Am J Hematol* 2012; 87: 465-471.
88. Palladini G, Barassi A, Perlini S, Milani P, Foli A, Russo P, Albertini R, Obici L, Lavatelli F, Sarais G, Casarini S, Moratti R, Melzi D Eril GV, Merlini G. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. *Amyloid*, 2011 Dec;18(4) 216-21.
89. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Montagna E, Russo P, Foli A, Milani P, Lavatelli F, Merlini G. Nutritional status and quality of life in outpatients with systemic immunoglobulin light-chain amyloidosis (AL) at diagnosis. *Ann Hematol* 2012 Mar; 91(3)399-406.
90. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, Nuvolone M, Brugnatelli S, Invernizzi R, Merlini G. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide. *Ann Hematol* 2012 Jan; 91(1)89-92.
91. Russo P, Palladini G, Foli A, Zenone Bragotti L, Milani P, Nuvolone M, Obici L, Perfetti V, Brugnatelli S, Invernizzi R, Merlini G. Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. *Amyloid* 2011; 18 Suppl 1: 87-88.
92. Palladini G, Foli A, Russo P, Milani P, Obici L, Lavatelli F, Merlini G. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone. *Clin Lymphoma Myeloma Leuk* 2011; 11: 143-145.
93. Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Zenone Bragotti L, Obici L, Moratti R, Melzi d'Eril GV, Merlini G. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. *Blood* 2010; 116: 3426-30.

Pavia, December 1, 2022